Chinese Journal of Dermatology ›› 2022, Vol. 55 ›› Issue (6): 508-510.doi: 10.35541/cjd.20210694
• Research Reports • Previous Articles Next Articles
Wen Guangdong1, Mao Dandan1, Zhang Yuanyuan2, Dou Yuanqing1, Zhao Pei1, Wu Chenyu1, Zhang Jianzhong1
Received:
2021-09-22
Revised:
2021-12-20
Online:
2022-06-15
Published:
2022-06-02
Contact:
Zhang Jianzhong
E-mail:rmzjz@126.com
Supported by:
Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 55(6): 508-510.doi:10.35541/cjd.20210694
[1] | Weidner T, Illing T, Elsner P. Primary localized cutaneous amyloidosis: a systematic treatment review[J]. Am J Clin Dermatol, 2017,18(5):629⁃642. doi: 10.1007/s40257⁃017⁃0278⁃9. |
[2] | Tursen U, Kaya TI, Dusmez D, et al. Case of generalized lichen amyloidosis[J]. Int J Dermatol, 2003,42(8):649⁃651. doi: 10.1046/j.1365⁃4362.2003.01949_2.x. |
[3] | Humeda Y, Beasley J, Calder K. Clinical resolution of generalized lichen amyloidosis with dupilumab: a new alternative therapy[J]. Dermatol Online J, 2020,26(12):13030/qt64s0s466. |
[4] | Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis ⁃ a systematic review[J]. J Dermatolog Treat, 2021,32(1):19⁃28. doi: 10.1080/09546634.2019.1689227. |
[5] | Geller S. Interleukin 4 and interleukin 13 inhibition: a promising therapeutic approach in bullous pemphigoid[J]. J Am Acad Dermatol, 2020,83(1):37⁃38. doi: 10.1016/j.jaad.2020.03.017. |
[6] | Aoki K, Ohyama M, Mizukawa Y. A case of lichen amyloidosis associated with atopic dermatitis successfully treated with dupilumab: a case report and literature review[J]. Dermatol Ther, 2021,34(4):e15005. doi: 10.1111/dth.15005. |
[7] | 宋志强, 王欢. 特应性皮炎的治疗进展:新药物、新手段、新模式[J]. 中华皮肤科杂志, 2021,54(2):161⁃164. doi: 10.35541/cjd.20201028. |
[8] | 程少为, 陈懿德, 兰东, 等. 原发性皮肤淀粉样变患者血清中IL⁃4及IgE水平测定[J]. 中国皮肤性病学杂志, 2001,15(3):165⁃166. doi: 10.3969/j.issn.1001⁃7089.2001.03.009. |
[9] | Tey HL, Cao T, Nattkemper LA, et al. Pathophysiology of pruritus in primary localized cutaneous amyloidosis[J]. Br J Dermatol, 2016,174(6):1345⁃1350. doi: 10.1111/bjd.14391. |
[10] | He A, Zampella JG, Kwatra SG. Interleukin⁃31 receptor and pruritus associated with primary localized cutaneous amyloidosis[J]. Br J Dermatol, 2016,175(2):433. doi: 10.1111/bjd.14510. |
[11] | Ko MJ, Peng YS, Chen HY, et al. Interleukin⁃31 is associated with uremic pruritus in patients receiving hemodialysis[J]. J Am Acad Dermatol, 2014,71(6):1151⁃1159.e1. doi: 10.1016/j.jaad.2014.08.004. |
[1] | Working Group for Atopic Dermatitis, Chinese Society of Dermatology, Working Group for Children′s Diseases, Chinese Society of Dermatology. Treatment of atopic dermatitis with dupilumab: an expert consensus [J]. Chinese Journal of Dermatology, 2022, 55(6): 465-470. |
[2] | Zhao Liuqi, Chen Yan, Chen Danyang, Fan Birao, Wang Rui, Shang Panpan, Chen Xixue, Zhu Xuejun, Wang Mingyue. Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study [J]. Chinese Journal of Dermatology, 2022, 55(6): 480-485. |
[3] | Huang Xin, Chen Xiaoyun, Li Yaping, Liang Xingkun, Zhang Guiying, Zhou Ying, Zhan Yi, Luo Shuaihantian, Liao Jieyue, Xiao Rong, Long Hai. Efficacy and safety of dupilumab in the treatment of 123 cases of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(6): 486-493. |
[4] | Zhang Xiao, Chen Fengming, Liu Lin, Luo Li, Guo Jin, Gao Tianwen, Shi Qiong. Analysis of clinicopathological features and prognosis of 163 cases of stage Ⅰ cutaneous melanoma [J]. Chinese Journal of Dermatology, 2022, 55(5): 389-394. |
[5] | Hu Yebei, Song Xiuzu. Tranexamic acid for the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(5): 460-462. |
[6] | Wang Ao, Yao Xu. Mechanisms of pruritus in atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 357-361. |
[7] | Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 0(4): 20200767-e20200767. |
[8] | Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2021 [J]. Chinese Journal of Dermatology, 2022, 55(4): 369-372. |
[9] | Li Wei, Yin Huibin. Heterogeneity across skin sites in atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 349-352. |
[10] | Tian Jing, Liang Yuan, Shen Chunping, Zhao Mutong, Wang Yang, Wang Shan, Jiao Lei, Ma Lin. Analysis of short-term efficacy and safety of the first subcutaneous injection of dupilumab in the treatment of moderate-to-severe childhood atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 299-303. |
[11] | Liu Bo, Song Xiaoting, Li Ruoyu, Zhao Zuotao. Clinical efficacy and safety of dupilumab in the treatment of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 295-298. |
[12] | Environmental and Occupational Skin Disease Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Group on Children, Chinese Society of Dermatology. Expert consensus on clinical application of wet-wrap therapy for atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 289-294. |
[13] | Liu Yuzhen, Zeng Rong, Zheng Nana, Duan Zhimin, Xu Haoxiang, Wu Qiuju, Lin Tong, Li Min. Effect of different incubation time of aminolevulinic acid on photodynamic inhibition of Propionibacterium acnes biofilms [J]. Chinese Journal of Dermatology, 2022, 55(3): 208-212. |
[14] | Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement (2022) [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195. |
[15] | Jiao Xiaoyan, Yin Guangwen, Yin Yakun, Li Dongqin. Clinical analysis of 25 cases of herpes zoster during pregnancy or the perinatal period [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210384-e20210384. |
|